Pricing

Turning Point Therapeutics Inc (TPTX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Athena M. Countouriotis
Employees:
250
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
858-926-5251
Turning Point Therapeutics, Inc. engages in designing and developing therapies that target genetic drivers of cancer. Its lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC)
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available